Table 8.
Serious hypertension comparison of nine VEGFR-TKIs
| AXI | |||||||||
|
0.91 (0.24, 4.04) |
CAB | ||||||||
|
0.85 (0.27, 3.30) |
0.95 (0.22, 3.92) |
LEN | |||||||
|
2.12 (0.49, 9.37) |
2.35 (0.47, 10.30) |
2.49 (0.55, 10.42) |
NIN | ||||||
|
2.60 (0.85, 10.58) |
2.91 (0.84, 11.18) |
3.06 (0.97, 11.30) |
1.24 (0.35, 5.41) |
PAZ | |||||
|
16.62 (6.90, 53.02) ƚ |
18.33 (6.77, 56.72) ƚ |
19.47 (7.94, 54.59) ƚ |
7.87 (2.76, 28.34) ƚ |
6.37 (3.02, 13.30) ƚ |
PLA | ||||
|
2.21 (0.73, 8.38) |
2.42 (0.71, 9.23) |
2.56 (0.82, 8.78) |
1.04 (0.29, 4.55) |
0.84 (0.29, 2.29) |
0.13 (0.06, 0.27)* |
REG | |||
|
2.76 (1.28, 7.84) ƚ |
3.02 (1.02, 9.92) ƚ |
3.23 (1.33, 8.53) ƚ |
1.32 (0.44, 4.65) |
1.06 (0.42, 2.53) |
0.17 (0.10, 0.27)* |
1.26 (0.52, 2.97) |
SOR | ||
|
1.31 (0.43, 4.74) |
1.46 (0.50, 4.11) |
1.53 (0.46, 5.16) |
0.63 (0.18, 2.39) |
0.50 (0.16, 1.42) |
0.08 (0.03, 0.17)* |
0.60 (0.20, 1.69) |
0.47 (0.20, 1.05) |
SUN | |
|
2.35 (0.50, 11.40) |
2.58 (0.50, 12.28) |
2.72 (0.56, 11.93) |
1.14 (0.21, 5.62) |
0.89 (0.20, 3.21) |
0.14 (0.04, 0.40)* |
1.05 (0.25, 3.89) |
0.84 (0.21, 2.74) |
1.77 (0.40, 6.94) |
VAN |
Data presented with ORs (95% CrI) in the column-defining drug compared with the row-defining drug
OR odds ratio, CrI credible interval, PLA placebo, AXI axitinib, CAB cabozantinib, LEN lenvatinib, NIN nintedanib, PAZ pazopanib, REG regorafenib, SOR sorafenib, SUN sunitinib, VAN vandetanib
*ORs more than 1 favors row-defining drug
ƚ: ORs less than 1 favors column-defining drug